Oragenics (OGEN) : Traders are bullish on Oragenics (OGEN) as it has outperformed the S&P 500 by a wide margin of 2.45% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 7.46%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 7.92% in the last 1 week, and is up 5% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
Oragenics (NYSEMKT:OGEN): The stock opened at $0.78 on Friday but the bulls could not build on the opening and the stock topped out at $0.82 for the day. The stock traded down to $0.74 during the day, due to lack of any buying support eventually closed down at $0.78 with a loss of -0.51% for the day. The stock had closed at $0.78 on the previous day. The total traded volume was 101,304 shares.
The stock has recorded a 20-day Moving Average of 6.73% and the 50-Day Moving Average is 21.1%. Oragenics Inc. has dropped 9.65% during the last 3-month period . Year-to-Date the stock performance stands at -48.2%.
Oragenics, Inc. is a biopharmaceutical company. The Company develops, markets and sells oral cavity probiotics products for humans and pets, under the brand names Evora and ProBiora. The Company is developing its antibiotic product candidate, MU1140, as well as other homolog antibiotic product candidates, researching Live Biotherapeutic Products (LBPs), commercializing its ProBiora3 probiotic products and has other product candidates, including SMaRT Replacement Therapy positioned for out licensing or partnering. MU1140 is an antibiotic that is active against all Gram positive bacteria. ProBiora3 is a blend of three naturally occurring strains of beneficial bacteria, including Streptococcus oralis KJ3, Streptococcus uberis KJ2 and Streptococcus rattus JH145, which promotes fresher breath, whiter teeth and supports overall oral health. LPT3-04 is a natural occurring dietary substance that supports weight loss in overweight men and women.